Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[2]
Stein DS, Moore KH..
Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians..
Pharmacotherapy, (2001), 21 pp. 11-34
[3]
Spence R, Kati W, Andeson K, Johnson KA..
Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors..
Science, (1995), 267 pp. 988-93
[4]
Flexner C..
Drug therapy: HIV-protease inhibitors..
N Eng J Med, (1998), 338 pp. 1281-92
[5]
Imamichi T..
Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors..
Curr Pharm Des, (2004), 10 pp. 4039-53
[6]
De Clercq E..
New developments in anti-HIV chemotherapy..
Biochim Biophys Acta, (2002), 1587 pp. 258-75
[7]
de Mendoza C, Gallego O, Soriano V..
Mechanisms of resistance to antiretroviral drugs¬clinical implications..
AIDS Rev, (2002), 4 pp. 64-82
[8]
Hammer S, Katzenstein D, Hughes M, Gundacker H, Schooley RT, Haubrich RH, et al..
A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts from 200 to 500 per cubic millimeter..
N Engl J Med, (1996), 335 pp. 1081-90
[9]
Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, et al..
Abacavir-lamivudine-zidovudine vs. indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults..
JAMA, (2001), 285 pp. 1155-63
[10]
Ray A, Olson L, Fridland A..
Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir..
Antimicrob Agents Chemother, (2004), 48 pp. 1089-95
[11]
John M, Moore C, James I, Nolan D, Upton RP, McKinnon EJ, et al..
Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy..
AIDS, (2001), 15 pp. 717-23
[12]
Moyle G, Wilkins E, Leen C, Cheesbrough A, Reynolds B, Gazzard BG..
Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use..
AIDS, (2000), 14 pp. 1453-4
[13]
Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al..
A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in human immunodeficiency virus infection..
J Infect Dis, (2002), 185 pp. 1251-60
[14]
García-Benayas T, Blanco F, De la Cruz J, Soriano V, González-Lahoz J..
Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy..
AIDS, (2003), 17 pp. 921-4
[15]
Gallant J, Staszewski S, Pozniak A, DeJesus E, Suleiman JM, Miller MD, et al..
Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in combination therapy in antiretroviral-naive patients: a 3-year randomized trial..
JAMA, (2004), 292 pp. 191-201
[16]
Schooley R, Ruane P, Myers R, Beall G, Lampiris H, Berger D, et al..
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomised, double-blind study..
AIDS, (2002), 16 pp. 1257-63
[17]
Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al..
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: arandomized open-label trial. The 2NN study..
Lancet, (2004), 363 pp. 1253-63
[18]
Martínez E, Arnaiz J, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al..
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with HIV infection..
N Engl J Med, (2003), 349 pp. 1036-46
[19]
Seminari E, Maggiolo F, Villani P, Suter F, Pan A, Regazzi MB, et al..
Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1+ patients heavily pretreated with nucleoside analogues and protease inhibitors..
J Acquir Immune Defic Syndr, (1999), 22 pp. 453-60
[20]
Dragsted U, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, et al..
MaxCmin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial..
J Infect Dis, (2003), 188 pp. 635-42
[21]
Acosta E, Wu H, Hammer S, Yu S, Kuritzkes DR, Walawander A, et al, for the Adult AIDS Clinical Trials Group 5055 Protocol Team..
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals..
J Acquir Immune Defic Syndr, (2004), 37 pp. 1358-66
[22]
Albrecht M, Bosch R, Hammer S, Liou SH, Kessler H, Para MF, et al..
AIDS Clinical Trials Group 364 Study Team. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection..
N Engl J Med, (2001), 345 pp. 398-407
[23]
Chapman T, Plosker G, Perry C..
Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection..
Drugs, (2004), 64 pp. 2101-24
[24]
Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al..
Lopinavir ritonavir versus nelfinavir for the initial treatment of HIV infection..
N Engl J Med, (2002), 346 pp. 2039-46
[25]
Barreiro P, Rendón A, Rodríguez-Nóvoa S, Soriano V..
Atazanavir: The advent of a new generation of more convenient protease inhibitors..
HIV Clin Trials, (2005), 6 pp. 50-61
[27]
Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al..
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia..
N Engl J Med, (2003), 348 pp. 2186-95
